Laserfiche WebLink
4. Implementing or supporting pilot programs for the voluntary testing of <br />individuals who enter local (city or county) criminal justice facilities, and for <br />those identified with OUD, offer induction of evidence -based treatment, <br />including MAT. <br />5. Support treatment and recovery courts for persons with OUD and any co- <br />occurring SUD/MH issues, but only if they provide referrals to evidence -informed <br />treatment, including MAT. <br />6. Provide evidence -informed treatment, including MAT, recovery support, harm <br />reduction, or other appropriate services to individuals with OUD and any co- <br />occurring SUD/MH issues who are incarcerated in jail or prison. <br />7. Provide evidence -informed treatment, including MAT, recovery support, harm <br />reduction, or other appropriate services to individuals with OUD and any co- <br />occurring SUD/MH issues who are leaving jail or prison have recently left jail or <br />prison, are on probation or parole, are under community corrections <br />supervision, or are in re-entry programs or facilities. <br />8. Support critical time interventions (CTI), particularly for individuals living with <br />dual -diagnosis OUD/serious mental illness, and services for individuals who face <br />immediate risks and service needs and risks upon release from correctional <br />settings. <br />9. Provide training on best practices for addressing the needs of criminal -justice - <br />involved persons with OUD and any co-occurring SUD/MH issues to law <br />enforcement, correctional, or judicial personnel or to providers of treatment, <br />recovery, harm reduction, case management, or other services offered in <br />connection with any of the strategies described in this section; <br />10. Provide training to Justices of the Peace on unattended deaths involving drug <br />use and reimbursement of transfer to and costs or expenses of a Medical <br />Examiner to enhance better death understanding, statistics and recording on <br />overdose involved deaths. <br />E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, <br />INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME <br />1. Support evidence -informed, promising, or emerging treatment, including MAT, <br />recovery services and supports, and prevention services for pregnant women — <br />or women who could become pregnant — who have OUD and any co-occurring <br />SUD/MH issues. <br />2. Fund Screening, Brief Intervention and Referral to Treatment (SBIRT) programs <br />and training for all health care providers to identify women with potential opioid <br />C <br />